Compare ZM & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZM | KVUE |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Specialty Chemicals |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1B | 32.9B |
| IPO Year | 2019 | 2023 |
| Metric | ZM | KVUE |
|---|---|---|
| Price | $87.35 | $19.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 11 |
| Target Price | ★ $94.14 | $19.45 |
| AVG Volume (30 Days) | 3.8M | ★ 19.0M |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.82% |
| EPS Growth | ★ 92.52 | 40.74 |
| EPS | ★ 1.42 | 0.25 |
| Revenue | $4,868,769,000.00 | ★ $15,124,000,000.00 |
| Revenue This Year | $7.30 | $4.85 |
| Revenue Next Year | $3.96 | $2.63 |
| P/E Ratio | ★ $61.34 | $79.22 |
| Revenue Growth | ★ 4.36 | N/A |
| 52 Week Low | $69.15 | $14.02 |
| 52 Week High | $114.74 | $22.87 |
| Indicator | ZM | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 42.50 | 75.51 |
| Support Level | $86.74 | $16.83 |
| Resistance Level | $91.96 | N/A |
| Average True Range (ATR) | 3.22 | 0.35 |
| MACD | -0.06 | 0.14 |
| Stochastic Oscillator | 34.54 | 98.01 |
Zoom Communications provides a video-first communications platform that connects people through frictionless video, voice, chat, and content sharing. The company's cloud-native platform enables video experiences and connects users across various devices and locations in a single meeting. Zoom has launched a variety of communications-related solutions, including Zoom Phone and Zoom Contact Center. The firm was founded in 2011 and serves companies of all sizes from all industries around the world.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.